Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2009
02/05/2009US20090035353 Non-absorbent articles containing additives
02/05/2009US20090035352 Drug Delivery Particle
02/05/2009US20090035350 Polymers for implantable devices exhibiting shape-memory effects
02/05/2009US20090035348 Dissolution of arterial plaque
02/05/2009US20090035345 Nuclear Receptors Agonists for Treatment of Atherosclerosis and/or Related Cardiovascular Disease
02/05/2009US20090035342 Antimicrobial Devices and Compositions
02/05/2009US20090035340 Preservative compositions for moist wipes
02/05/2009US20090035339 Methods of Inactivating Viruses
02/05/2009US20090035338 Inverse emulsions comprising avermectins and cosmetic/dermatological applications thereof
02/05/2009US20090035336 Isoflavone nanoparticles and use thereof
02/05/2009US20090035332 Pharmaceutical formulation
02/05/2009US20090035331 Systems and Methods for Targeted and Controlled Delivery of Agents
02/05/2009US20090035329 Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions
02/05/2009US20090035324 N-(2-(4-(4-fluoro(benzyl-d6)carbamoyl)-5-hydroxy-1-(methyl-d3)-6-oxo-1,6-dihydropyrimidin-2-yl)-(1,3-d6-propan)-2-yl)-5-(methyl-d3)-1,3,4-oxadiazole-2-carboxamide; use in methods of treating HIV infections
02/05/2009US20090035315 Method of Improving Treatments in Rheumatic and Arthritic Diseases
02/05/2009US20090035314 Method and pharmaceutical composition for preventing or treating diseases associated with inflammation
02/05/2009US20090035313 Compounds
02/05/2009US20090035312 Tumor angiogenesis associated genes and a method for their identification
02/05/2009US20090035310 Cancer treatment
02/05/2009US20090035309 Substituted Benzazoles and Methods of Their Use as Inhibitors of RAF Kinase
02/05/2009US20090035306 Quinazolinone modulators of tgr5
02/05/2009US20090035302 Rage Antagonists As Agents To Reverse Amyloidosis And Diseases Associated Therewith
02/05/2009US20090035301 Methods for diagnosing and treating bladder cancer
02/05/2009US20090035299 Methods and compositions for treating diseases targeting MABA1
02/05/2009US20090035298 Methods to treat alzheimer's disease or other amyloid beta accumulation associated disorders
02/05/2009US20090035297 Methods for treating diabetes
02/05/2009US20090035296 Compounds and methods for treatment and diagnosis of chlamydial infection
02/05/2009US20090035294 Lipopolysaccharide fractions of vitreoscilla filiformis useful for stimulating the synthesis of anti-microbial peptides of the skin
02/05/2009US20090035292 Use of phosphatases to treat neuroblastomas and medulloblastomas
02/05/2009US20090035291 Therapeutic use of adpase enhanced apyrases
02/05/2009US20090035287 Atrial natriuretic peptide (anp) splice variants and methods of using same
02/05/2009US20090035282 Pluripotent embryonic-like stem cells derived from teeth and uses thereof
02/05/2009US20090035281 Combination of interleukin-6 antagonists and antiproliferative drugs
02/05/2009US20090035279 Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma
02/05/2009US20090035277 Hepatitis C Virus Nucleic Acid Vaccine
02/05/2009US20090035275 Methods and formulations for protecting cells, and for treating diseases and conditions by optimizing the intracellular concentration of NAD
02/05/2009US20090035274 Treatment and/or prevention of cancer and/or arthritis
02/05/2009US20090035271 Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
02/05/2009US20090035268 Tetrazolyl acyclic hepatitis c serine protease inhibitors
02/05/2009US20090035267 Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
02/05/2009US20090035266 Immunogenic peptides and methods of use
02/05/2009US20090035265 Compositions and Methods for Targeted Delivery of Factors
02/05/2009US20090035256 Modified interleukin 10 polypeptide for use in treatment and prevention of neuropathic pain, neurological and inflammatory disorders
02/05/2009US20090035251 Method of applying an injectable filler
02/05/2009US20090035250 Compositions and methods for treating cavity conditions
02/05/2009US20090035249 Method of inhibiting proliferation of Escherichia coli
02/05/2009US20090035248 Fast Degrading Polymers
02/05/2009US20090035242 Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And Linear Or Branched Silicone
02/05/2009US20090035228 Skin and surface disinfectant compositions containing botanicals
02/05/2009US20090035225 RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA
02/05/2009US20090035224 Methods of Using Albuterol and Calcium Activated Potassium Channel Openers
02/05/2009US20090035219 CB1 receptor antagonists and uses thereof
02/05/2009US20090035215 Radiofluorination
02/05/2009US20090032049 Ventilated Device for Delivery of Agents to and through the Human Scalp
02/05/2009DE19963179B4 Substituierte 1- und 2-Naphthol-Mannichbasen Substituted 1- and 2-naphthol Mannich bases
02/05/2009DE19805822B4 11-Acetyl-12,13-dioxabicyclo[8.2.1]tridecenon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel 11-acetyl-12,13-dioxabicyclo [8.2.1] tridecenon derivatives, processes for their preparation and pharmaceutical compositions containing them
02/05/2009DE102008033254A1 Verfahren zur Herstellung eines einphasischen pharmazeutischen Präparates zur oralen Therapie der Regulierung des Blutdruckes A method for producing a pharmaceutical preparation for the oral therapy einphasischen the regulation of blood pressure
02/05/2009DE102007036076A1 Dipeptoid-Produgs und ihre Verwendung Dipeptoid prodrugs and their use
02/05/2009DE102007036075A1 Prodrugs und ihre Verwendung Prodrugs and their use
02/05/2009DE102007035741A1 Stabilisierung kosmetischer oder dermatologischer Formulierung enthaltend Mandelsäure Stabilization of cosmetic or dermatological formulation containing mandelic acid
02/05/2009CA2853992A1 Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
02/05/2009CA2823372A1 Pharmaceutical composition for treating wounds and related methods
02/05/2009CA2719824A1 Methods and compositions for treating schizophrenia using antipsychotic combination therapy
02/05/2009CA2705625A1 Improved formulations of candesartan
02/05/2009CA2700004A1 Novel immunotherapy strategy
02/05/2009CA2698749A1 Sublingual fentanyl spray
02/05/2009CA2698305A1 Effervescent solid pharmaceutical composition comprising dextrose and process for its preparation
02/05/2009CA2698170A1 Prodrugs of 2-amino-6- ( { [2- (4-chlorphenyl) -1, 3-thiaz0l-4-yl] methyl}thio) -4- [4- ( 2 -hydroxyethoxy) phenyl] pyridin-3, 5-dicarbonitrile
02/05/2009CA2697345A1 Stereoselective process for preparing purine dioxolane nucleoside derivatives
02/05/2009CA2697147A1 Cyclic inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
02/05/2009CA2696005A1 5'-substituted adenosynes, preparation thereof and use as inhibitors of s-adenosylmethionine decarboxylase
02/05/2009CA2695660A1 Adefovir dipivoxil crystalline monohydrate form
02/05/2009CA2695384A1 Bi-dentate compounds as kinase inhibitors
02/05/2009CA2695304A1 Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions
02/05/2009CA2695297A1 Substituted cc-1065 analogs and their conjugates
02/05/2009CA2695282A1 Medicaments and methods for inhibition of non-ocular scarring
02/05/2009CA2695259A1 Metabolites and derivatives of ambrisentan
02/05/2009CA2695257A1 Anti-inflammatory composition
02/05/2009CA2695214A1 Transdermal administration of (2s)-(4e)-n-methyl-5-(3-(5-is0pr0p0xypyridin)yl)-4-penten-2-amine
02/05/2009CA2695203A1 Improved method for the synthesis of substituted formylamines and substituted amines
02/05/2009CA2695197A1 Integrated photoactive agents and uses thereof
02/05/2009CA2695196A1 Naphthyridine derivatives as potassium channel modulators
02/05/2009CA2695178A1 Methods for producing aripiprazole suspension and freeze-dried formulation
02/05/2009CA2695156A1 Vinyl-aryl derivatives for inflammation and immune-related uses
02/05/2009CA2695148A1 Pyridine compounds for inflammation and immune-related uses
02/05/2009CA2695143A1 Heterocycle-aryl compounds for inflammation and immune-related uses
02/05/2009CA2695114A1 Pyrazole compounds and their use as raf inhibitors
02/05/2009CA2695071A1 The use of benzamide derivatives for the treatment of cns disorders
02/05/2009CA2694953A1 Compositions including androgen receptor degradation (ard) enhancers and methods of prophylactic or therapeutic treatment of skin disorders and hair loss
02/05/2009CA2694928A1 Micro-rnas that control myosin expression and myofiber identity
02/05/2009CA2694927A1 Pharmaceutical composition for treating wounds and related methods
02/05/2009CA2694925A1 Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
02/05/2009CA2694887A1 Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
02/05/2009CA2694724A1 Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer
02/05/2009CA2694663A1 5-phenyl-isoxazole-3-carboxamide derivatives as trpv1 modulators
02/05/2009CA2694639A1 Benzamidine derivatives, process for the preparation thereof and pharmaceutical composition for preventing or treating osteoporosis comprising the same
02/05/2009CA2694638A1 Preventive or therapeutic agent for diseases caused by abnormal bone metbolism
02/05/2009CA2694635A1 Uses of trientine and penicillamine as countermeasures to metal contamination
02/05/2009CA2694608A1 A process for the preparation of almotriptan and a synthetic intermediate usable in said process
02/05/2009CA2694567A1 Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity and intermediate thereof